Kimberly Yonkers to Treatment Outcome
This is a "connection" page, showing publications Kimberly Yonkers has written about Treatment Outcome.
Connection Strength
0.733
-
Yonkers KA, Altemus M, Gilstad-Hayden K, Kornstein SG, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?: A Randomized Controlled Trial. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):320-325.
Score: 0.103
-
Yonkers KA, Dyck IR, Keller MB. An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. Psychiatr Serv. 2001 May; 52(5):637-43.
Score: 0.090
-
Forray A, Martino S, Gilstad-Hayden K, Kershaw T, Ondersma S, Olmstead T, Yonkers KA. Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic. Addict Behav. 2019 09; 96:156-163.
Score: 0.078
-
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Oct; 72(10):1037-44.
Score: 0.061
-
Yonkers KA, Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol. 2013 Oct; 33(5):614-20.
Score: 0.053
-
Yonkers KA, Smith MV, Lin H, Howell HB, Shao L, Rosenheck RA. Depression screening of perinatal women: an evaluation of the healthy start depression initiative. Psychiatr Serv. 2009 Mar; 60(3):322-8.
Score: 0.039
-
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3):492-501.
Score: 0.030
-
Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
Score: 0.029
-
Brawman-Mintzer O, Yonkers KA. New trends in the treatment of anxiety disorders. CNS Spectr. 2004 Aug; 9(8 Suppl 7):19-27.
Score: 0.028
-
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Arch Womens Ment Health. 2003 Nov; 6(4):287-92.
Score: 0.027
-
Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin Pharmacother. 2002 Jul; 3(7):979-91.
Score: 0.024
-
Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry. 2002 Jul; 63(7):610-5.
Score: 0.024
-
Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 2000 Feb; 61(2):101-9.
Score: 0.021
-
Yonkers KA, Zlotnick C, Allsworth J, Warshaw M, Shea T, Keller MB. Is the course of panic disorder the same in women and men? Am J Psychiatry. 1998 May; 155(5):596-602.
Score: 0.018
-
Xu X, Yonkers KA, Ruger JP. Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial. BMC Pregnancy Childbirth. 2017 03 07; 17(1):83.
Score: 0.017
-
Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. Mod Probl Pharmacopsychiatry. 1997; 25:146-66.
Score: 0.017
-
Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997; 58 Suppl 14:4-10; discussion 11-3.
Score: 0.017
-
Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014 Jan-Feb; 36(1):13-8.
Score: 0.013
-
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr; 85(3):275-82.
Score: 0.007
-
Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry. 2004 Oct; 161(10):1864-71.
Score: 0.007
-
Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
Score: 0.007
-
Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
Score: 0.006
-
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000 Sep; 157(9):1445-52.
Score: 0.005
-
Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry. 1997 Mar; 154(3):390-5.
Score: 0.004
-
Shelton RC, Davidson J, Yonkers KA, Koran L, Thase ME, Pearlstein T, Halbreich U. The undertreatment of dysthymia. J Clin Psychiatry. 1997 Feb; 58(2):59-65.
Score: 0.004
-
Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swartz AR, Reich J, Lavori PW. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis. 1994 May; 182(5):290-6.
Score: 0.003